Psilocybin

This article was originally published on Psychedelic Spotlight and appears here with permission. Magic mushrooms come in all shapes and sizes, but which ones are the most potent? We rank the strongest magic mushrooms by potency Psychedelics are having a moment. Once relegated to the fringes of...

Researchers at the University of Texas (UT) Dell Medical School in Austin will use brain scans to examine responses following treatment with psilocybin and 5-MeO-DMT for combatants suffering from post-traumatic stress disorder (PTSD), traumatic brain injuries and other related conditions. The...

Silo Pharma Inc. (NASDAQ: SILO) has agreed with Columbia University to an extension of the psychedelics biotech company's option to license certain treatments currently under development, including Alzheimer’s disease and stress-induced anxiety. The compounds being...

Psychedelic -or psilocybin- mushrooms have demonstrated a potential to treat such conditions as depression, anxiety and addiction, yet they are still a mystery in terms of how they evolved and what role they play in nature. This is what a group of scientists at the...

The current clinical scenario sets psilocybin as one of the most advanced psychedelics, expected to become legally approved in the US sometime between the 2023-2024 period and to become available as of January 2023 within local assisted therapy in Oregon. Now PsyBio Therapeutics Corp. (OTCQB: PSYBF...

This article by Emma Stone was originally published on Microdose and appears here with permission. Borrowing from ancient Eastern teachings, Eckhart Tolle once reflected: “The secret of life is to die before you die, and find out there is no death.” This seemingly cryptic maxim conveys...

Biopharma R&D company Mindset Pharma Inc. (OTCQB: MSSTF) has performed preclinical screening studies and selected MSP-2020 as the lead psychedelic drug clinical candidate and MSP-2003 as the second backup drug candidate, both belonging to its Family 2 next-gen psychedelic drug program done in...

According to information procured exclusively by Benzinga ahead of an official announcement, global psychedelics company Silo Wellness Inc. (OTCQB: SILFF) (CSE: SILO) (FSE: 3K7A) is acquiring Dyscovry Science Ltd., a Toronto-based biotech company focused on biosynthetic manufacturing of...

Clinical-stage developer of psychedelic compounds Tryp Therapeutics Inc. (OTCQB: TRYPF) filed two provisional patent applications - one for psilocybin therapy for fibromyalgia and another expanding psilocybin-based TRP-8803 development’s IP.   Tryp's Psilocybin-For-...

This article was originally published on Leafly and appears here with permission.  Magic mushrooms are making waves. You can stream Michael Pollan’s docuseries How to Change Your Mind on Netflix, listen to quarterback Aaron Rodgers sing the praises of psychedelic mushrooms on a...

This article by Alexa Julianne was originally published on Psychedelic Spotlight and appears here with permission. With mounting evidence to support the use of psychedelics in treating serious disorders like PTSD, depression, and anxiety — the sector is now beginning to focus on more...

Alberta-based ATMA Journey Centers Inc. has received Health Canada’s approval to move forward with its N500 Phase II psilocybin clinical study investigating the potential relief of COVID-19-associated mental health challenges in frontline healthcare professionals while documenting their...

Jamaica is getting its own ecotourism and psilocybin microdosing resort and retreat center. The cliffside, beachfront resort, dubbed Go Natural Jamaica, is operated by publicly traded psychedelics company Silo Wellness (OTC: SILFF) and located in Long Bay, Portland, Jamaica. “We have been...

In Victoria, Australian health officials are proposing to restrict permits currently allowing patients with mental illnesses to access psychedelics in a therapeutic framework back to research and clinical trials “approved by a human research ethics committee....

Psychedelics R&D company Mindset Pharma (OTCQB: MSSTF) has filed no less than 16 national applications, including countries within the main South East Asian markets, for one of its key families of next-generation psychedelic compounds. The company recently announced the creation of three...